Why the study?
Despite the benefits of statins and injectable biologics, new and safe oral agents are needed to address classical lipid targets, triglyceride-rich lipoproteins, and lipoprotein(a).
Answers are grounded in this paper and cite their sources.
Recent advances in synthetic pharmacotherapies provide new, potentially safe, and effective options for managing dyslipidemias and addressing residual cardiovascular risk beyond traditional statin therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sirtori et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: